Protagonist Therapeutics (PTGX) Current Deferred Revenue (2017 - 2026)

Protagonist Therapeutics has reported Current Deferred Revenue for 10 years, with the latest figure at $6.3 million in Q1 2026.

• Quarterly Current Deferred Revenue fell 62.82% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (down 62.82% YoY) and the FY2025 annual result came in at $9.5 million, down 49.45% from the prior year.
• Current Deferred Revenue declined to $6.3 million in Q1 2026 per PTGX's latest filing, from $9.5 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $45.0 million in Q1 2024 and troughed at $3000.0 in Q3 2023.
• A 5-year average of $11.9 million and a median of $11.9 million in 2025 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue plunged 98.57% in 2022, then jumped 656433.33% in 2024.
• Over 5 years, Current Deferred Revenue stood at $69000.0 in 2022, then sank by 95.65% to $3000.0 in 2023, then surged by 629600.0% to $18.9 million in 2024, then tumbled by 49.45% to $9.5 million in 2025, then tumbled by 34.22% to $6.3 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $6.3 million, $9.5 million, and $14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.